Janssen Biotech Inc is in-licensing a Janus Kinase (JAK) inhibitor for rheumatoid arthritis from Astellas Pharma Inc – a second US pharma company to secure access in recent months to a new small molecule compound for this disease. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
